Bright Minds Biosciences Inc.
DRUG
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1,703.20% | -325.40% | -142.00% | 37.78% | 84.14% |
| Total Depreciation and Amortization | -4.28% | 1.67% | 398.37% | 8.75% | 4.47% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 933.06% | 240.56% | 12.08% | -138.48% | -183.63% |
| Change in Net Operating Assets | 54.49% | 1,439.85% | -66.64% | 37.51% | -238.21% |
| Cash from Operations | -409.31% | -354.79% | -193.39% | 12.08% | 52.42% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -11.56% | -11.35% | -11.76% | -8.27% | -5.89% |
| Issuance of Common Stock | 1.74% | 9,455.47% | 5,435.36% | 5,434.38% | 5,406.60% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -235.77% | -- | -- | -- | -- |
| Cash from Financing | -8.58% | 10,224.24% | 6,148.59% | 6,147.96% | 6,114.76% |
| Foreign Exchange rate Adjustments | -264.73% | 2,411.90% | 583.13% | 2,176.35% | 2,113.38% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -37.97% | 7,391.75% | 2,330.33% | 1,378.07% | 1,203.99% |